Skip to main content
Clinical Trials/NCT01948323
NCT01948323
Unknown
Not Applicable

Pregnancy-Related Obesity Prevention Through Education & Communication Technology in AFRICA:The PROTECT-AFRICA STUDY

University of Cape Town2 sites in 1 country1,200 target enrollmentSeptember 2013
ConditionsObesity

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obesity
Sponsor
University of Cape Town
Enrollment
1200
Locations
2
Primary Endpoint
To determine a clinically significant difference (absolute difference of ≥10%) in the proportion of participants who gain > 12kg throughout study period will be less in the intervention group compared to the the non-intervention group.
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this study is to investigate whether overweight but not obese pregnant African women having unlimited access to a health education-information technology (IT) based intervention package gain weight within the acceptable range of 8-12 kg during the pregnancy period.

Therefore, we hypothesize that unlimited access to health education via an IT-based intervention package has the potential to reduce the onset of obesity in African pregnant women.

To date (Aug 2015), 95% of patients have been recruited, 1320 potential subjects have been screened and 150 enrolled into the study

Registry
clinicaltrials.gov
Start Date
September 2013
End Date
December 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Prof. Karen Sliwa

Professor

University of Cape Town

Eligibility Criteria

Inclusion Criteria

  • body-mass index (BMI) range of 25.1-29.9 kg/m2
  • Weeks of pregnancy: 16-20
  • singleton pregnancy

Exclusion Criteria

  • Evidence of pre-existing cardiovascular disease or a metabolic disorder (i.e. gestational diabetes)

Outcomes

Primary Outcomes

To determine a clinically significant difference (absolute difference of ≥10%) in the proportion of participants who gain > 12kg throughout study period will be less in the intervention group compared to the the non-intervention group.

Time Frame: Mother: Baseline (16-20 weeks pregnancy), 24 weeks, 32 weeks, day of delivery, 6 weeks & 12 weeks postpartum

Secondary Outcomes

  • Change in plasma Vitamin C levels in both the mother and newborn(Mother: Baseline (16-20 weeks pregnancy), 24 weeks, 32 weeks, day of delivery, 6 weeks & 12 weeks postpartum; newborn: day of delivery, 6 weeks old, 12 weeks old)
  • Change in blood pressure profiles(Mother: Baseline (16-20 weeks pregnancy), 24 weeks, 32 weeks, day of delivery, 6 weeks & 12 weeks postpartum; newborn: day of delivery, 6 weeks old, 12 weeks old)
  • Improved resting heart rate(Mother: Baseline (16-20 weeks pregnancy), 24 weeks, 32 weeks, day of delivery, 6 weeks & 12 weeks postpartum; newborn: day of delivery, 6 weeks old, 12 weeks old)
  • Clinically normal C-reactive protein levels (<1 mg/dL)(Mother: Baseline (16-20 weeks pregnancy), 24 weeks, 32 weeks, day of delivery, 6 weeks & 12 weeks postpartum; newborn: day of delivery, 6 weeks old, 12 weeks old)
  • Improved awareness of food choices(Mother: Baseline (16-20 weeks pregnancy), 24 weeks, 32 weeks, 6 weeks postpartum)
  • Change in body composition (fat percentage, body water percentage, bone mass, muscle mass, bone density and visceral fat) of mother.(Mother: Baseline (12-16 weeks pregnancy), 24 weeks, 32 weeks, day of delivery, 6 weeks & 12 weeks postpartum)
  • To determine what women actually know (and how much they understand) about the risk factors during their pregnancy.(Mother: Baseline (16-20 weeks pregnancy), 24 weeks, 32 weeks, day of delivery, 6 weeks & 12 weeks postpartum)
  • Cost saving potential of intervention from a societal perspective.(September 2015)
  • Apgar score >3(Newborn: Day of delivery)

Study Sites (2)

Loading locations...

Similar Trials